Market leadership Position LifeCell within the Acelity family as part of a global leader in advanced wound therapeutics and regenerative medicine, highlighting scale, cross-border reach (80+ countries), and a strong portfolio to support enterprise bidding and hospital network opportunities.

Regenerative tissue focus Target surgeons and centers performing breast reconstruction, hernia repair, and reconstructive procedures using ALLODERM, STRATTICE, and related matrices, emphasizing cost- effectiveness and speed-to-healing through acellular matrix solutions.

Acelity product ecosystem Leverage synergies with adjacent Acelity offerings such as V.A.C. therapy, PREVENA incision management, and ABTHERA dressings to cross-sell comprehensive wound care bundles to hospitals, wound centers, and ambulatory surgical centers.

Adoptive tech advantage Highlight digital and operational tools within the tech stack (Azure, site metrics, analytics) to offer data-driven outcomes, case studies, and outcome tracking for new and existing customers seeking measurable healing and cost reduction.

Financial and growth potential Target mid-sized healthcare systems and regional networks with revenue in the $250M–$500M band, aligning LifeCell’s regenerative matrices with their procurement cycles, budgetary timelines, and value-based care initiatives to drive renewal and expansion opportunities.